New cash for collaboration to develop new drugs for treating cardiomyopathy

5th January 2017

A global cardiomyopathy research collaboration which aims to develop new drugs for hypertrophic  and dilated cardiomyopathy is to benefit from another $45 million.

The collaboration is between the pharmaceutical companies MyoKardia, based in America, and the French multinational Sanofi which has large worldwide prescription sales.

MyoKardia has begun trialling a gene therapy treatment for hypertrophic cardiomyopathy (HCM) and hopes early this year to start phase one clinical development of a drug to establish normal heart contractility in inherited dilated cardiomyopathy (DCM).

The company has just announced that Sanofi is to extend the research agreement with the multi-million dollar payment this month.

“MyoKardia and Sanofi share a passion for science and a commitment to patients,” said Dr Tassos Gianakakos, MyoKardia’s chief executive officer. “The continuation of this research collaboration provides valuable support for further innovation and development of critically important therapies for patients with serious cardiovascular diseases.”

Two of MyoKardia’s three programmes are focussed on inherited cardiomyopathy.  Its lead product candidate, MYK-461, it designed to target the underlying cause of hypertrophic cardiomyopathy in patients with a particular genetic make-up.

Dr Gianakakos said that by targeting an underlying molecular defect causing HCM, it was hoped the treatment could restore normal heart muscle contraction and relaxation, and reduce or prevent disease progression.

It’s proposed drug for dilated cardiomyopathy, called MYK-491, is  on track for submission to the United States Food and Drug Administration’s investigational new drug programme (IND) to initiate clinical studies.